CHRS insider trading
NasdaqGM HealthcareCoherus Oncology, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Company website: www.coherus.com
CHRS insider activity at a glance
FilingIQ has scored 367 insider transactions for CHRS since Mar 10, 2015. The most recent filing in our index is dated Jan 23, 2026.
Across the full history, 4 open-market purchases
and 131 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CHRS insider trades is 60.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CHRS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CHRS?
- FilingIQ tracks 367 Form 4 insider transactions for CHRS (Coherus Oncology, Inc.), covering filings from Mar 10, 2015 onwards. 0 of those were filed in the last 90 days.
- Are CHRS insiders net buyers or net sellers?
- Across the full Form 4 history for CHRS, 4 transactions (1%) were open-market purchases and 131 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CHRS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CHRS in?
- Coherus Oncology, Inc. (CHRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $246.63M.
Methodology & sources
Every CHRS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.